GlycoMimetics Dirección
Dirección controles de criterios 2/4
El CEO de GlycoMimetics' es Harout Semerjian , nombrado en Aug 2021, tiene una permanencia de 2.67 años. compensación anual total es $2.39M, compuesta por 26.7% salario y 73.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.039% de las acciones de la empresa, por valor de $42.75K. La antigüedad media del equipo directivo y de la junta directiva es de 2.7 años y 7.6 años, respectivamente.
Información clave
Harout Semerjian
Chief Executive Officer (CEO)
US$2.4m
Compensación total
Porcentaje del salario del CEO | 26.7% |
Permanencia del CEO | 2.7yrs |
Participación del CEO | 0.04% |
Permanencia media de la dirección | 2.7yrs |
Promedio de permanencia en la Junta Directiva | 7.6yrs |
Actualizaciones recientes de la dirección
Recent updates
GlycoMimetics Can Become A Game Changer In Blood Cancers
Mar 21Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?
Mar 20GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real
Jan 30Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?
Nov 19Will GlycoMimetics (NASDAQ:GLYC) Spend Its Cash Wisely?
Jan 30Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely
Oct 06GlycoMimetics has a new Chief Medical Officer
Sep 06GlycoMimetics GAAP EPS of $0.25 beats by $0.53, revenue of $75K
Aug 03GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely
Jun 04GlycoMimetics Positive Data For AML Therapy Increasingly Likely
Mar 16Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Nov 20We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully
Aug 20GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study
May 26Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year
May 12GlycoMimetics EPS beats by $0.04
May 03Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Mar 26GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares
Feb 19GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings
Jan 24How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?
Dec 28New data from GlycoMimetics highlights the efficacy Rivipansel in vaso-occlusive crisis in sickle cell disease
Dec 07Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Dec 07The Investment Case For GlycoMimetics
Nov 17Análisis de compensación del CEO
Fecha | Compensación total | Salario | Ingresos de la empresa |
---|---|---|---|
Dec 31 2023 | US$2m | US$638k | -US$37m |
Sep 30 2023 | n/a | n/a | -US$38m |
Jun 30 2023 | n/a | n/a | -US$37m |
Mar 31 2023 | n/a | n/a | -US$42m |
Dec 31 2022 | US$1m | US$614k | -US$47m |
Sep 30 2022 | n/a | n/a | -US$54m |
Jun 30 2022 | n/a | n/a | -US$63m |
Mar 31 2022 | n/a | n/a | -US$64m |
Dec 31 2021 | US$3m | US$244k | -US$63m |
Compensación vs. Mercado: La compensación total de Harout($USD2.39M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD668.06K).
Compensación vs. Ingresos: La compensación de Harout ha aumentado mientras la empresa no es rentable.
CEO
Harout Semerjian (53 yo)
2.7yrs
Permanencia
US$2,389,418
Compensación
Mr. Harout Semerjian serves as Chief Executive Officer, President & Director of GlycoMimetics, Inc., since August 6, 2021. He served as President and Chief Executive Officer of Immunomedics Inc. since Apri...
Equipo directivo
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
CEO, President & Director | 2.7yrs | US$2.39m | 0.039% $ 45.0k | |
Co-Founder & Director | 21.3yrs | US$96.00k | 0.99% $ 1.1m | |
Senior VP & CFO | 12.3yrs | US$1.30m | 0.056% $ 64.6k | |
Senior VP & Chief Medical Officer | 1.6yrs | US$1.15m | 0.58% $ 675.7k | |
Vice President of Accounting | 5.3yrs | sin datos | sin datos | |
General Counsel & Company Secretary | 5yrs | sin datos | sin datos | |
Senior VP & Chief Commercial Officer | 2.2yrs | sin datos | 0.22% $ 250.2k | |
Senior VP & Chief Business Officer | 1.2yrs | sin datos | 0.25% $ 290.1k | |
Senior Vice President of Technical Operations | less than a year | sin datos | sin datos |
2.7yrs
Permanencia media
53yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de GLYC se considera experimentado (2.7 años antigüedad media).
Miembros de la Junta
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
CEO, President & Director | 2.7yrs | US$2.39m | 0.039% $ 45.0k | |
Co-Founder & Director | 21.3yrs | US$96.00k | 0.99% $ 1.1m | |
Independent Director | 8.1yrs | US$118.50k | 0.15% $ 177.2k | |
Independent Chairman of the Board | 10.1yrs | US$138.00k | 0.038% $ 44.4k | |
Independent Director | 7.1yrs | US$100.50k | 0.057% $ 66.1k | |
Independent Director | 5.4yrs | US$111.00k | 0.0081% $ 9.5k | |
Independent Director | 6.8yrs | US$105.00k | 0.091% $ 105.5k | |
Independent Director | 9.8yrs | US$111.00k | 0.056% $ 65.4k |
7.6yrs
Permanencia media
64yo
Promedio de edad
Junta con experiencia: La junta directiva de GLYC se considera experimentada (7.6 años de antigüedad promedio).